Overview

A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
It is a phase II, randomized, double-blind, placebo-controlled study of P2202 in patients of type 2 diabetes mellitus, inadequately controlled with a stable dose of metformin or sulfonylurea or both.
Phase:
Phase 2
Details
Lead Sponsor:
Piramal Enterprises Limited